Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR044
MIFTS: 35

Ovarian Carcinosarcoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Ovarian Carcinosarcoma

About this section

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 53 59 15
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 53 59
Malignant Mixed Müllerian Tumor of the Ovary 53 59
Ovarian Malignant Mixed Müllerian Tumor 53 59
Mmmt of the Ovary 53 59
Malignant Mixed Mullerian Tumor of the Ovary 53
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Carcinosarcoma of Ovary 73
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

59
malignant mixed müllerian tumor of the ovary
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6170
NCIt 50 C9192
Orphanet 59 ORPHA213512
UMLS via Orphanet 74 C0392998
ICD10 via Orphanet 34 C56
UMLS 73 C0392998
Sources

Summaries for Ovarian Carcinosarcoma

About this section
NIH Rare Diseases : 53 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to carcinosarcoma and inguinal hernia. An important gene associated with Ovarian Carcinosarcoma is TUBB3 (Tubulin Beta 3 Class III). The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and small intestine.

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Sources

Related Diseases for Ovarian Carcinosarcoma

About this section

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 10.7
2 inguinal hernia 10.1
3 bilateral breast cancer 10.1
4 uterine corpus serous adenocarcinoma 10.1 ERBB2 TUBB3
5 uterine corpus cancer 10.1 ERBB2 TUBB3
6 stomach disease 10.0 ERBB2 TUBB3
7 paralytic squint 10.0 FUT2 TUBB3
8 teratoma 10.0
9 female reproductive system disease 10.0 ERBB2 TUBB3
10 reproductive system disease 10.0 ERBB2 TUBB3
11 gonadal disease 10.0 ERBB2 TUBB3
12 breast neuroendocrine neoplasm 10.0 ERBB2 SYP
13 gastrointestinal system cancer 10.0 ERBB2 TUBB3
14 mixed cell type cancer 10.0 ERBB2 SYP
15 granulosa cell tumor of the ovary 10.0 ERBB2 SYP
16 respiratory system disease 10.0 CD274 TUBB3
17 olfactory nerve neoplasm 10.0 SYP TUBB3
18 tubular adenocarcinoma 10.0 ERBB2 SYP
19 pineal gland cancer 9.9 SYP TUBB3
20 pineocytoma 9.9 SYP TUBB3
21 cranial nerve malignant neoplasm 9.9 SYP TUBB3
22 sweat gland cancer 9.9 ERBB2 SYP
23 pineal parenchymal tumor of intermediate differentiation 9.9 SYP TUBB3
24 adult medulloblastoma 9.9 SYP TUBB3
25 respiratory system cancer 9.9 CD274 ERBB2 TUBB3
26 central nervous system cancer 9.9 SYP TUBB3
27 nervous system cancer 9.9 SYP TUBB3
28 myeloma, multiple 9.9
29 tubulin, beta 9.9
30 angiosarcoma 9.9
31 melanoma 9.9
32 cystic teratoma 9.9
33 cystadenocarcinoma 9.9
34 serous cystadenocarcinoma 9.9
35 rhabdomyosarcoma 9.9
36 liposarcoma 9.9
37 mature teratoma 9.9
38 pleomorphic liposarcoma 9.9
39 cerebellar degeneration 9.9
40 paraneoplastic cerebellar degeneration 9.9
41 merkel cell carcinoma 9.9 CD274 SYP
42 thymus cancer 9.9 CD274 SYP
43 endocrine gland cancer 9.8 ERBB2 SYP TUBB3
44 nervous system disease 9.7 SYP TUBB3
45 lung cancer 9.4 CD274 ERBB2 SYP TUBB3

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma
Sources

Symptoms & Phenotypes for Ovarian Carcinosarcoma

About this section
Sources

Drugs & Therapeutics for Ovarian Carcinosarcoma

About this section

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
8
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
9
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
10
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
13 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Alkylating Agents Phase 3,Phase 2
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2
20
Isophosphamide mustard Phase 3 0
21 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
22 Serotonin Agents Phase 3
23 Anti-Allergic Agents Phase 3
24 Serotonin Antagonists Phase 3
25 Histamine H1 Antagonists Phase 3
26
Histamine Phosphate Phase 3 51-74-1 65513
27 Antipruritics Phase 3
28 Neurotransmitter Agents Phase 3
29 Dermatologic Agents Phase 3
30 Histamine Antagonists Phase 3
31 Gastrointestinal Agents Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
34
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
36
Everolimus Approved Phase 2 159351-69-6 6442177
37
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
39
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
40 Antiviral Agents Phase 2
41 Antimetabolites, Antineoplastic Phase 2
42 Immunologic Factors Phase 2,Phase 1
43 Immunosuppressive Agents Phase 2
44 Anti-Infective Agents Phase 2
45 Antimetabolites Phase 2
46 Topoisomerase Inhibitors Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Mitogens Phase 2,Phase 1
50 Endothelial Growth Factors Phase 2,Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
6 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
7 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
8 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
9 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
10 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
11 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
12 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
13 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
14 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
15 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
16 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Not yet recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
17 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
18 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
19 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
20 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
21 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
22 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
23 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
24 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
25 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Terminated NCT00904514

Search NIH Clinical Center for Ovarian Carcinosarcoma

Sources

Genetic Tests for Ovarian Carcinosarcoma

About this section
Sources

Anatomical Context for Ovarian Carcinosarcoma

About this section

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

41
Ovary, Lymph Node, Small Intestine, Lung, Thymus, Pineal
Sources

Publications for Ovarian Carcinosarcoma

About this section

Articles related to Ovarian Carcinosarcoma:

(show all 45)
# Title Authors Year
1
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
2
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
3
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. ( 30345126 )
2018
4
Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. ( 30022854 )
2018
5
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. ( 30147940 )
2018
6
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. ( 28791266 )
2017
7
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. ( 28679774 )
2017
8
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. ( 28790096 )
2017
9
Clinical Significance of Programmed Death Liganda891 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. ( 28125702 )
2017
10
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
11
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
12
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
13
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
14
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
15
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
16
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
17
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEAr), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
18
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. ( 25341582 )
2014
19
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
20
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
21
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
22
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
23
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
24
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
25
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
26
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
27
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
28
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
29
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
30
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
31
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
32
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
33
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
34
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
35
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
36
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
37
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
38
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
39
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
40
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
41
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
42
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
43
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
44
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
45
MR images of ovarian carcinosarcoma. ( 10646984 )
1999
Sources

Variations for Ovarian Carcinosarcoma

About this section
Sources

Expression for Ovarian Carcinosarcoma

About this section
Search GEO for disease gene expression data for Ovarian Carcinosarcoma.
Sources

Pathways for Ovarian Carcinosarcoma

About this section
Sources

GO Terms for Ovarian Carcinosarcoma

About this section
Sources

Sources for Ovarian Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....